Adelaida García-Velasco1,2, Lluís Zacarías-Pons3, Helena Teixidor3, Marc Valeros3, Raquel Liñan1, M Carmen Carmona-Garcia1,2, Montse Puigdemont2,3, Walter Carbajal1, Raquel Guardeño1, Núria Malats4, Eric Duell5, Rafael Marcos-Gragera2,3,6. 1. Medical Oncology Department, Josep Trueta Universitary Hospital, Catalan Institute of Oncology, Av de França, 17007 Girona, Spain. 2. Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), C/Dr. Castany, s/n, 17190 Salt, Spain. 3. Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Av. França, s/n, 17004 Girona, Spain. 4. Genetic and Molecular Epidemiology Group, Spanish National Cancer Research (CNIO) and CIBERONC, 28029 Madrid, Spain. 5. Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 08908 Barcelona, Spain. 6. Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), 28029 Madrid, Spain.
Abstract
(1) Background: We investigated the incidence and survival trends for pancreatic cancer (PC) over the last 25 years in the Girona region, Catalonia, Spain; (2) Methods: Data were extracted from the population-based Girona Cancer Registry. Incident PC cases during 1994-2015 were classified using the International Classification of Diseases for Oncology Third Edition (ICD-O-3). Incidence rates age-adjusted to the European standard population (ASRE) and world standard population (ASRW) were obtained. Trends were assessed using the estimated annual percentage of change (EAPC) of the ASRE13. Observed and relative survivals (RS) were estimated with the Kaplan-Meier and Pohar Perme methods, respectively; (3) Results: We identified 1602 PC incident cases. According to histology, 44.4% of cases were exocrine PC, 4.1% neuroendocrine, and 51.1% malignant-non-specified. The crude incidence rate (CR) for PC was 11.43 cases-per-100,000 inhabitants/year. A significant increase of incidence with age and over the study period was observed. PC overall 5-year RS was 7.05% (95% confidence interval (CI) 5.63; 8.84). Longer overall survival was observed in patients with neuroendocrine tumours (5-year RS 61.45%; 95% CI 47.47; 79.55). Trends in 5-year RS for the whole cohort rose from 3.27% (95% CI 1.69-6.35) in 1994-1998 to 13.1% (95% CI 9.98; 17.2) in 2010-2015; (4) Conclusions: Incidence rates of PC in Girona have increased in the last two decades. There is a moderate but encouraging increase in survival thorough the study period. These results can be used as baseline for future research.
(1) Background: We investigated the incidence and survival trends for pancreatic cancer (PC) over the last 25 years in the Girona region, Catalonia, Spain; (2) Methods: Data were extracted from the population-based Girona Cancer Registry. Incident PC cases during 1994-2015 were classified using the International Classification of Diseases for Oncology Third Edition (ICD-O-3). Incidence rates age-adjusted to the European standard population (ASRE) and world standard population (ASRW) were obtained. Trends were assessed using the estimated annual percentage of change (EAPC) of the ASRE13. Observed and relative survivals (RS) were estimated with the Kaplan-Meier and Pohar Perme methods, respectively; (3) Results: We identified 1602 PC incident cases. According to histology, 44.4% of cases were exocrine PC, 4.1% neuroendocrine, and 51.1% malignant-non-specified. The crude incidence rate (CR) for PC was 11.43 cases-per-100,000 inhabitants/year. A significant increase of incidence with age and over the study period was observed. PC overall 5-year RS was 7.05% (95% confidence interval (CI) 5.63; 8.84). Longer overall survival was observed in patients with neuroendocrine tumours (5-year RS 61.45%; 95% CI 47.47; 79.55). Trends in 5-year RS for the whole cohort rose from 3.27% (95% CI 1.69-6.35) in 1994-1998 to 13.1% (95% CI 9.98; 17.2) in 2010-2015; (4) Conclusions: Incidence rates of PC in Girona have increased in the last two decades. There is a moderate but encouraging increase in survival thorough the study period. These results can be used as baseline for future research.
Authors: Ramon Clèries; Alberto Ameijide; Maria Buxó; Mireia Vilardell; José Miguel Martínez; Francisco Alarcón; David Cordero; Ana Díez-Villanueva; Yutaka Yasui; Rafael Marcos-Gragera; Maria Loreto Vilardell; Marià Carulla; Jaume Galceran; Ángel Izquierdo; Víctor Moreno; Josep M Borràs Journal: Gac Sanit Date: 2018-01-19 Impact factor: 2.139
Authors: Melina Arnold; Mark J Rutherford; Aude Bardot; Jacques Ferlay; Therese M-L Andersson; Tor Åge Myklebust; Hanna Tervonen; Vicky Thursfield; David Ransom; Lorraine Shack; Ryan R Woods; Donna Turner; Suzanne Leonfellner; Susan Ryan; Nathalie Saint-Jacques; Prithwish De; Carol McClure; Agnihotram V Ramanakumar; Heather Stuart-Panko; Gerda Engholm; Paul M Walsh; Christopher Jackson; Sally Vernon; Eileen Morgan; Anna Gavin; David S Morrison; Dyfed W Huws; Geoff Porter; John Butler; Heather Bryant; David C Currow; Sara Hiom; D Max Parkin; Peter Sasieni; Paul C Lambert; Bjørn Møller; Isabelle Soerjomataram; Freddie Bray Journal: Lancet Oncol Date: 2019-09-11 Impact factor: 41.316
Authors: J Ferlay; M Colombet; I Soerjomataram; T Dyba; G Randi; M Bettio; A Gavin; O Visser; F Bray Journal: Eur J Cancer Date: 2018-08-09 Impact factor: 9.162
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: A Carrato; A Falcone; M Ducreux; J W Valle; A Parnaby; K Djazouli; K Alnwick-Allu; A Hutchings; C Palaska; I Parthenaki Journal: J Gastrointest Cancer Date: 2015-09
Authors: Lei Huang; Lina Jansen; Yesilda Balavarca; Masoud Babaei; Lydia van der Geest; Valery Lemmens; Liesbet Van Eycken; Harlinde De Schutter; Tom B Johannesen; Maja Primic-Žakelj; Vesna Zadnik; Marc G Besselink; Petra Schrotz-King; Hermann Brenner Journal: BMC Med Date: 2018-08-21 Impact factor: 8.775